An Evaluation of NGM120 in a Randomized, Double-blind, Placebo-controlled Study in Participants With Colorectal Cancer Who Have Cancer Cachexia.

a study on Colorectal Cancer Cancer Cachexia Colorectal Tumor

Summary

Eligibility
for people ages 18 years and up (full criteria)
Location
at Los Angeles, California and other locations
Dates
study started
study ends around

Description

Summary

A multi-center evaluation of NGM120 in a randomized, double-blind, placebo-controlled study in participants with colorectal cancer who have cancer cachexia.

Official Title

A Phase 2, Multicenter, Randomized, Double Blind, Placebo-controlled Study to Assess the Efficacy, Safety, and Tolerability of NGM120 in Participants With Colorectal Cancer Who Have Cancer Cachexia

Details

Evaluation of Efficacy, Safety and Tolerability of NGM120 in a Phase 2, Randomized, Double-blind, Placebo-controlled, Multi-center Study in Participants with Colorectal Cancer who have Cancer Cachexia

Keywords

Colorectal Cancer, CRC (Colorectal Cancer), Cancer Cachexia, CRC, Colorectal Neoplasms, NGM120 Q4W, NGM120 Q8W

Eligibility

You can join if…

Open to people ages 18 years and up

  1. Documented active diagnosis of colorectal cancer.
  2. Cachexia defined by Fearon criteria of weight loss.
  3. Signed informed consent.

You CAN'T join if...

  1. Current active reversible causes of decreased food intake.
  2. Receiving tube feedings or parenteral nutrition at the time of Screening or Randomization.
  3. Have cachexia caused by other reasons.

Locations

  • NGM Clinical Study Site accepting new patients
    Los Angeles California 90095 United States
  • NGM Clinical Study Site accepting new patients
    Los Angeles California 90033 United States

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
NGM Biopharmaceuticals, Inc
Links
Sign up for this study
ID
NCT07033026
Phase
Phase 2 research study
Study Type
Interventional
Participants
Expecting 136 study participants
Last Updated
Contact us about this trial